# US 12,599,614 B2 · Methods and pharmaceutical compositions for the treatment and prophylaxis of microbial infectious diseases and associated inflammatory disorders and for the treatment and prophylaxis of aging and associated diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,614 B2 - Document ID: US12599614B2 - Status: Granted - Kind: B2 - Application number: 18/039,236 - Filed: 2021-12-13 - Published: 2024-01-04 - Granted: 2026-04-14 - Earliest claimed: 2020-12-14 - Assignees: Md Vault LLC - Applicants: Md Vault LLC - Inventors: Meng Hua Ng - Web page: https://patentgrep.com/patent/US12599614B2 ## CPC - A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil - A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine - A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin - A61K 31/415: 1,2-Diazoles - A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone - A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A pharmaceutical composition and method are provided which may be used for the treatment and prevention of various infections, diseases, and conditions. Preferably, the composition and method may be used for preventing and treating of aging and aging associated disease and its use (or method). Preferably, the composition and method may be used for treating and prophylaxis of microbial infectious diseases and associated inflammatory disorders and its use (or method). The pharmaceutical composition according to the invention includes a therapeutic agent X or a pharmaceutically acceptable salt thereof; a therapeutic agent Y or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, in which the therapeutic agent X is a non-steroidal anti-inflammatory drug and the therapeutic agent Y is a fatty acid oxidation inhibitor. ## Claims ### Claim 1 A method of treating at least one of the following conditions in a subject in need thereof: Lung Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), and Idiopathic Pulmonary Fibrosis (IPF), wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 2 A method of treating a Chronic Wound in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 3 (depends on 2) The method of claim 2, wherein the Chronic Wound is a result of Diabetes. ### Claim 4 A method of treating Hair Loss in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 5 A method of treating Sarcopenia in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 6 A method of reducing senescence in a tissue or organ in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 7 A method of reversing fibrosis in a tissue or organ in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition that comprises a combination of therapeutic agent X and acceptable salts thereof and therapeutic agent Y and acceptable salts thereof, and wherein the therapeutic agent X is 2-acetoxybenzoic acid and the therapeutic agent Y is 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine. ### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7) The method according to any one of claims 1-7, wherein therapeutic agent X and therapeutic agent Y are included in separate dosage forms. ### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7) The method according to any one of claims 1-7, wherein therapeutic agent X and therapeutic agent Y are included in a single dosage form.